TY - JOUR
T1 - Clinical, humanistic, and economic burden of osteoarthritis among noninstitutionalized adults in the United States
AU - Zhao, X.
AU - Shah, D.
AU - Gandhi, K.
AU - Wei, W.
AU - Dwibedi, N.
AU - Webster, L.
AU - Sambamoorthi, U.
N1 - Funding Information:
Funding support for this study was provided by Regeneron Pharmaceuticals Inc . and Teva Pharmaceutical Industries Ltd .
Funding Information:
Funding support for this study was provided by Regeneron Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.The authors acknowledge E. Jay Bienen, PhD, for medical writing support during development of this manuscript, and Michele Salernitano of Ashfield Healthcare Communications (part of UDG Healthcare plc) for editorial support, funded by Teva Pharmaceutical Industries.
Funding Information:
The authors acknowledge E. Jay Bienen, PhD, for medical writing support during development of this manuscript, and Michele Salernitano of Ashfield Healthcare Communications (part of UDG Healthcare plc) for editorial support, funded by Teva Pharmaceutical Industries .
Publisher Copyright:
© 2019 Osteoarthritis Research Society International
PY - 2019/11
Y1 - 2019/11
N2 - Objective: To estimate the burden of osteoarthritis (OA) among noninstitutionalized adults (≥18 years of age) in the US. Design: Weighted nationally representative data from the 2015 Medical Expenditure Panel Survey were used to estimate OA prevalence in noninstitutionalized adults and compare adults with OA to those without OA for clinical (pain interference with activities [PIA], functional limitations), humanistic (health-related quality-of-life [HRQoL]) and economic outcomes (healthcare costs, wage loss). Productivity/wage loss was estimated among employed working-age adults (18–64 years). Multivariable regression analyses examined the associations between OA and outcomes. Results: In 2015, 10.5% (25.6 million) of noninstitutionalized US adults reported having any OA. Regression analyses indicated that adults with OA were significantly more likely than those without OA to report moderate (adjusted odds ratios [AOR] 1.99; 95% confidence interval [CI] 1.65–2.40] or severe PIA (AOR 2.59; 95% CI 2.21–3.04), any functional limitation (AOR 2.51; 95% CI 2.21–2.85), and poorer HRQoL on the SF-12 version 2 Physical Component Summary score (adjusted beta [standard error] −3.88 [0.357]; P < 0.001). Adjusted incremental annual total healthcare costs and lost wages among adults with OA relative to those without OA were $1778 and $189 per person, respectively, resulting in estimated national excess costs of $45 billion and $1.7 billion, respectively. Conclusions: OA affects approximately 10% of noninstitutionalized adults in the US, resulting in substantial clinical, humanistic, and economic burdens.
AB - Objective: To estimate the burden of osteoarthritis (OA) among noninstitutionalized adults (≥18 years of age) in the US. Design: Weighted nationally representative data from the 2015 Medical Expenditure Panel Survey were used to estimate OA prevalence in noninstitutionalized adults and compare adults with OA to those without OA for clinical (pain interference with activities [PIA], functional limitations), humanistic (health-related quality-of-life [HRQoL]) and economic outcomes (healthcare costs, wage loss). Productivity/wage loss was estimated among employed working-age adults (18–64 years). Multivariable regression analyses examined the associations between OA and outcomes. Results: In 2015, 10.5% (25.6 million) of noninstitutionalized US adults reported having any OA. Regression analyses indicated that adults with OA were significantly more likely than those without OA to report moderate (adjusted odds ratios [AOR] 1.99; 95% confidence interval [CI] 1.65–2.40] or severe PIA (AOR 2.59; 95% CI 2.21–3.04), any functional limitation (AOR 2.51; 95% CI 2.21–2.85), and poorer HRQoL on the SF-12 version 2 Physical Component Summary score (adjusted beta [standard error] −3.88 [0.357]; P < 0.001). Adjusted incremental annual total healthcare costs and lost wages among adults with OA relative to those without OA were $1778 and $189 per person, respectively, resulting in estimated national excess costs of $45 billion and $1.7 billion, respectively. Conclusions: OA affects approximately 10% of noninstitutionalized adults in the US, resulting in substantial clinical, humanistic, and economic burdens.
KW - Burden of illness
KW - Functional limitations
KW - Health-related quality of life
KW - Medical costs
KW - Osteoarthritis
KW - Productivity loss
UR - http://www.scopus.com/inward/record.url?scp=85069837716&partnerID=8YFLogxK
U2 - 10.1016/j.joca.2019.07.002
DO - 10.1016/j.joca.2019.07.002
M3 - Article
C2 - 31299387
AN - SCOPUS:85069837716
SN - 1063-4584
VL - 27
SP - 1618
EP - 1626
JO - Osteoarthritis and Cartilage
JF - Osteoarthritis and Cartilage
IS - 11
ER -